Jeffrey W. Albers - Nov 1, 2021 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
CEO and President, Director
Signature
/s/ Ariel Hurley, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Nov 1, 2021
Transactions value $
-$500,750
Form type
4
Date filed
11/3/2021, 04:03 PM
Previous filing
Aug 30, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $75.1K +5K +2.65% $15.01 193K Nov 1, 2021 Direct F1
transaction BPMC Common Stock Sale -$576K -5K -2.58% $115.16 188K Nov 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -5K -4.76% $0.00 100K Nov 1, 2021 Common Stock 5K $15.01 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 This option was granted on February 3, 2016 and is fully vested as of the date hereof.